What is the Spero Therapeutics Inc. stock price forecast?

Spero Therapeutics Inc. is currently trading at $2.77. View real-time AI analysis on Alpha Lenz.

What is Spero Therapeutics Inc. insider trading activity?

View the latest insider trading data for Spero Therapeutics Inc. on Alpha Lenz.

What is Spero Therapeutics Inc.'s P/E ratio?

Spero Therapeutics Inc.'s P/E ratio is 18.1.

Spero Therapeutics Inc.

NASDAQ · SPRO

$2.77-0.14(-4.81%)Pre-market

Ask about Spero Therapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Spero Therapeutics Inc. trades at a P/E of 18.1 (fair value) with strong ROE of 16.3%.”

Ask for details →

Company Overview

SectorUnknown

IndustryUnknown

Company Statistics

FY 2025

Profile

$155.18MMarket Cap

$59.62MRevenue

0.00Shares Out

N/AEmployees

Margins

N/AGross

13.43%EBITDA

12.01%Operating

14.82%Pre-Tax

14.38%Net

Valuation

18.10P/E

2.63P/B

2.60EV/Sales

14.72EV/EBITDA

-12.29P/FCF

Growth (CAGR)

7.06%Rev 3Yr

197.00%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

9.55%ROA

16.31%ROE

7.98%ROIC

Financial Health

$40.27MCash & Cash Equivalents

$-30.37MNet Debt

16.77%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Spero Therapeutics Inc. trades at a P/E of 18.1 (fair value) with strong ROE of 16.3%.”

Ask for details →

Frequently Asked Questions

Spero Therapeutics Inc. (ticker: SPRO) is a company listed on NASDAQ in the Unknown sector (Unknown). Market cap is $155M.

The current price is $2.77 with a P/E ratio of 18.1x and P/B of 2.63x.

ROE is 16.31% and operating margin is 12.01%. Annual revenue is $60M.